Companies are increasingly arguing that it is no longer possible to justify the UK’s “voluntary scheme” to global boardrooms and investors as repayment rates in 2023 have surged to 26.5% of revenue, the Association of the British Pharmaceutical Industry (ABPI) said in a statement.
Tag Archive for: AbbVie
Drugmakers are prioritizing complex biotech medicines over treatments that can be given as pills because recent U.S. legislation gives biologics a longer runway before becoming subject to government price limits, top industry executives said this week.
Kite’s Christi Shaw, AbbVie’s Jag Dosanjh, and LexisNexis Risk Solution’s Liz Paulson earn top industry honors.
In a fireside chat at the 41st J.P. Morgan Healthcare Conference in San Francisco, CEO Rick Gonzalez said AbbVie is well-positioned for continued growth.
AbbVie Inc. on Tuesday raised its 2025 sales forecast of its newer immunology drugs Skyrizi and Rinvoq to more than $17.5 billion as it hopes to replace the loss of revenue from its blockbuster rheumatoid arthritis drug Humira.
AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.
The company is leaving industry groups Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization, according to reports.
Co-developed by J&J’s Janssen and AbbVie’s Pharmacyclics, ibrutinib stood out across several presentations at the 64th American Society of Hematology (ASH) annual meeting Saturday and Sunday.
Boston biopharma Karuna Therapeutics appointed Bill Meury as its new president and chief executive officer, succeeding its current head, Steve Paul, the company announced Tuesday. Meury starts on Jan. 3, 2023.
Following a development setback, MEI Pharma will pivot toward two earlier clinical-stage assets and cut 30% of its workforce in a strategic realignment, the company announced Monday.